Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Type 2 Diabetes
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
The study is being conducted to evaluate the efficacy and safety of HRS9531 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors…
- Trial name
- NCT06649344
- Testing
- HRS9531 Injection, Semaglutide Injection
- Where
- China
- Volunteers
- 884 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity, Overweight
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus
- Trial name
- NCT05669599
- Testing
- Maridebart Cafraglutide
- Where
- 78 sites in United States, Australia and 10 more
- Volunteers
- 592 people
- Sponsor
- Amgen
Type 2 Diabetes Mellitus
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus
This study will be the first evaluation of exenatide in adolescent subjects with type 2 diabetes mellitus and is designed to evaluate the blood levels of the drug (pharmacokinetics), the drug's biochemical and physiological…
- Trial name
- NCT00254254
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
- Trial name
- PIONEER 3 (NCT02607865)
- Testing
- semaglutide, sitagliptin
- Where
- 242 sites in United States, Argentina and 13 more
- Volunteers
- 1,864 people
- Sponsor
- Novo Nordisk A/S
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Type 2 Diabetes Mellitus
Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes
The purpose of this study is to obtain information on efficacy and safety of SHR3824 with metformin over 24 weeks and 52 weeks in metformin monotherapy poorly glycemic controlled chinese Type 2 Diabetes.
- Trial name
- NCT04390295
- Testing
- SHR3824, metformin
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Cocoa/Carob Polyphenols and Postprandial Changes in Type 2 Diabetes
The aim of this is study is to evaluate the effects of a single intake of a mixture of cacao and carob (rich in high molecular weight polyphenols) in postprandial metabolism in subjects with type 2 diabetes.
- Trial name
- CACAOBA (NCT04383639)
- Testing
- No product (A)/mixture of coca and carob together with breakfast (B)/mixture of coca and carob 10 h before breakfast (C)
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- National Research Council, Spain
Type 2 Diabetes Mellitus
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
This study is designed to evaluate the safety and tolerability of a range of single oral doses of LGD-6972 in healthy subjects. Additionally, the study will characterize the Pharmacokinetic profile in healthy subjects under fed…
- Trial name
- NCT01919684
- Testing
- LGD-6972
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Ligand Pharmaceuticals
Type 2 Diabetes Mellitus
Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)
The purpose of this study is to demonstrate the bioequivalence (BE) of Saxagliptin and Dapagliflozin from a 2.5-mg Saxagliptin/5-mg Dapagliflozin FDC tablet after oral administration relative to 2.5-mg Saxagliptin and 5-mg…
- Trial name
- NCT02060201
- Testing
- Saxagliptin, Dapagliflozin, Saxagliptin/Dapagliflozin FDC
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects
The purpose of this study was to investigate the effect of a high-fat meal on the levels of bexagliflozin in the blood in healthy subjects.
- Trial name
- NCT02820298
- Testing
- Bexagliflozin
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Theracos
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive…
- Trial name
- NCT00614055
- Testing
- insulin degludec/insulin aspart, insulin glargine, metformin
- Where
- 28 sites in France, Germany and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil
To demonstrate the bioequivalence of saxagliptin and metformin in a saxagliptin, 5-mg/metformin extended-release (XR), 500-mg, fixed-dose combination (FDC) tablet with saxagliptin, 5-mg and metformin, 500-mg XR tablets…
- Trial name
- NCT01365091
- Testing
- Saxagliptin/metformin fixed-dose combination (FDC), Saxagliptin, Metformin extended-release (XR)
- Where
- Brazil
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos
This trial is conducted in Europe. The aim of this trial is to evaluate the effect of Levemir® (insulin detemir) on glycaemic control, weight and incidence of hypoglycaemic events in insulin treated subjects with type 1 or type 2…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542489
- Testing
- insulin detemir, insulin aspart, human soluble insulin
- Where
- Slovakia
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone.
- Trial name
- NCT00528879
- Testing
- Dapagliflozin, Metformin
- Where
- 75 sites in United States, Argentina and 3 more
- Volunteers
- 915 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
This trial is conducted in Europe, and North and South America. The aim of this trial is to investigate if a dietary intervention has an effect on weight when initiating insulin treatment in subjects with type 2 diabetes…
- Trial name
- DIET™ (NCT01232491)
- Testing
- Insulin detemir, Dietary regimen
- Where
- 112 sites in United States, Argentina and 9 more
- Volunteers
- 611 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Lipid, Glycemic, and Insulin Responses to Meals Rich in Different Fatty Acids
A meal rich in very-long chain omega-3 fatty acids or oleic acid may lower postprandial insulin levels in comparison to a meal rich in linoleic acid or palmitic acid.
- Trial name
- NCT00479791
- Testing
- Test meals rich in different fatty acids
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes, Diabetes Mellitus, Type 2
Observational Study of NovoNorm® in Subjects With Diabetes
This study is conducted in Asia. The aim of this study is to review the safety and efficacy of Novonorm® (repaglinide) in post-marketing use.
- Trial name
- NCT01498913
- Testing
- repaglinide
- Where
- South Korea
- Volunteers
- 5,841 people
- Sponsor
- Novo Nordisk A/S
PreDiabetes
Insulin and Insulin Pulses During Fasting
Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes.
- Trial name
- NCT06424015
- Testing
- Intralipid and heparin, Saline
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Healthy Volunteers
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382
A Phase 1 study to evaluate the effect of MEDI0382 on PK and PD of warfarin and esmolol in healthy subjects.
- Trial name
- NCT03347968
- Testing
- MEDI0382, Warfarin, Esmolol
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01006291)
- Testing
- insulin degludec, insulin glargine
- Where
- 72 sites in Argentina, Finland and 12 more
- Volunteers
- 687 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.